Synthesis Capital

The firm's mandate covers alternative proteins (plant-based, precision fermentation, and cellular agriculture) as well as the enabling infrastructure — including bioreactors, feedstock engineering, and bioprocess optimization — that determines whether these technologies can scale to cost parity. It does not invest in conventional agriculture, food distribution, or restaurant tech.

The founding team's decade-plus tenure in food-tech venture, dating to CPT Capital's earliest investments in the sector, gives Synthesis access to scientist-founders and university spinouts before generalist venture firms enter competitive processes. The firm also draws on relationships with sovereign wealth funds and family offices that co-invested alongside CPT Capital in prior fund cycles (per Bloomberg, 2023).

Synthesis invests primarily as a lead or co-lead in early-stage and growth rounds, with no publicly disclosed fund-of-funds program. Its debut vehicle accepted commitments from institutional LPs rather than operating a co-investment club for family offices or high-net-worth individuals. The firm has not announced a dedicated co-investment vehicle as of mid-2026.